Apex Biotechnology Corp (1733) - Total Liabilities
Based on the latest financial reports, Apex Biotechnology Corp (1733) has total liabilities worth NT$494.69 Million TWD (≈ $15.59 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Apex Biotechnology Corp (1733) investment intensity to see how much of total assets are deployed in long-term investments.
Apex Biotechnology Corp - Total Liabilities Trend (2002–2024)
This chart illustrates how Apex Biotechnology Corp's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 1733 asset base.
Apex Biotechnology Corp Competitors by Total Liabilities
The table below lists competitors of Apex Biotechnology Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Arihant Capital Markets Limited
NSE:ARIHANTCAP
|
India | Rs5.51 Billion |
|
China Container Terminal Corp
TW:2613
|
Taiwan | NT$7.02 Billion |
|
Investcorp India Acquisition Corp. Class A ordinary share
NASDAQ:IVCA
|
USA | $5.71 Million |
|
Graha Andrasentra Propertindo Tbk PT
JK:JGLE
|
Indonesia | Rp439.35 Billion |
|
Economic Investment Trust Ltd
TO:EVT
|
Canada | CA$158.27 Million |
|
Zuari Agro Chemicals Limited
NSE:ZUARI
|
India | Rs15.46 Billion |
|
Axis Corporation
TWO:6292
|
Taiwan | NT$551.14 Million |
|
Wrap Technologies Inc
NASDAQ:WRAP
|
USA | $1.99 Million |
Liability Composition Analysis (2002–2024)
This chart breaks down Apex Biotechnology Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Apex Biotechnology Corp balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Apex Biotechnology Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Apex Biotechnology Corp (2002–2024)
The table below shows the annual total liabilities of Apex Biotechnology Corp from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$595.70 Million ≈ $18.77 Million |
+19.12% |
| 2023-12-31 | NT$500.07 Million ≈ $15.75 Million |
-28.23% |
| 2022-12-31 | NT$696.81 Million ≈ $21.95 Million |
-24.00% |
| 2021-12-31 | NT$916.91 Million ≈ $28.89 Million |
-8.79% |
| 2020-12-31 | NT$1.01 Billion ≈ $31.67 Million |
-11.61% |
| 2019-12-31 | NT$1.14 Billion ≈ $35.83 Million |
+26.14% |
| 2018-12-31 | NT$901.70 Million ≈ $28.41 Million |
-12.87% |
| 2017-12-31 | NT$1.03 Billion ≈ $32.61 Million |
+34.67% |
| 2016-12-31 | NT$768.49 Million ≈ $24.21 Million |
+0.50% |
| 2015-12-31 | NT$764.69 Million ≈ $24.09 Million |
-1.78% |
| 2014-12-31 | NT$778.52 Million ≈ $24.53 Million |
-3.11% |
| 2013-12-31 | NT$803.47 Million ≈ $25.31 Million |
+9.29% |
| 2012-12-31 | NT$735.18 Million ≈ $23.16 Million |
+89.11% |
| 2011-12-31 | NT$388.76 Million ≈ $12.25 Million |
+21.26% |
| 2010-12-31 | NT$320.60 Million ≈ $10.10 Million |
+5.70% |
| 2009-12-31 | NT$303.31 Million ≈ $9.56 Million |
+37.11% |
| 2008-12-31 | NT$221.21 Million ≈ $6.97 Million |
+8.01% |
| 2007-12-31 | NT$204.80 Million ≈ $6.45 Million |
+4.63% |
| 2006-12-31 | NT$195.73 Million ≈ $6.17 Million |
-12.37% |
| 2005-12-31 | NT$223.36 Million ≈ $7.04 Million |
+73.62% |
| 2004-12-31 | NT$128.64 Million ≈ $4.05 Million |
+5.44% |
| 2003-12-31 | NT$122.00 Million ≈ $3.84 Million |
+36.76% |
| 2002-12-31 | NT$89.21 Million ≈ $2.81 Million |
-- |
About Apex Biotechnology Corp
Apex Biotechnology Corp. researches, develops, manufactures, and sells home care medical devices by using biosensor technology worldwide. The company offers blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1C, and ketone monitoring systems, as well as coagulation and multifunctional self-testing. It also provides pesticide residue check systems; and care management and tele-health s… Read more